Skip to main content
Clinical Trials/NL-OMON36274
NL-OMON36274CompletedNot Applicable

Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure - DEFEAT-HF

Medtronic Trading NL BV0 sites10 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
10

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • LVEF of 35% or less
  • NYHA functional Class III
  • QRS duration less than 120 ms
  • LVEDD of 55 mm - 80 mm
  • Receiving stable medical therapy for heart failure prior to enrollment.

Exclusion Criteria

  • Temporal stop of anticoagulation therapy poses an unacceptable health risk
  • Inability to perform an exercise capacity test
  • Pregnancy or likely to get pregant during the course of the study
  • CABG/PCI/BMS procedures within the past 90 days
  • Heart transplant
  • Acute Coronary Syndrome within the past 90 days
  • Congenital heart disease with significant hemodynamic shunting
  • Reversible cardiomyopathy (i.e. tachycardia induced heart failure)
  • Diagnosed unstable angina pectoris
  • Unstable coronary artery disease
  • CRT device implanted
  • non-Medtronic ICD, pacemaker or defibrillation lead
  • Patient already has a neurostimulator
  • (see p15-16)

Investigators

Sponsor
Medtronic Trading NL BV

Similar Trials

Determining the Feasibility of Spinal Cord... | Clinical Trial